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Background: Distal embolization (DE) is a potential complication of percutaneous
atherectomy and other endovascular procedures that can lead to poor outcomes for the
patient and escalated costs for hospitals. Embolic protection (EP) devices have been
shown in several studies to have a low failure rate, and thus reduce the incidence of
these events. This study compared inpatient hospital costs and resource utilization in
two non-coronary (presumed lower extremity) atherectomy patient populations: (1)
a DE event group, and (2) a SpiderFX Embolic Protection Device (Covidien,
Plymouth, MN) group.
Methods: All inpatient discharges for atherectomy of non-coronary vessels (ICD-9-
CM procedure code 39.50) were selected from a comprehensive hospital admissions
database (Premier Perspective CY2006-Q3 of CY2012). Of these, DE patients were
identiﬁed using ICD-9-CM diagnosis codes (444.xx, 434.0, and 434.1). Patients using
a SpiderFX Device were identiﬁed using a product keyword search. Discharges in
both the groups were matched 1:1 using propensity score methodology, adjusting for
age, gender, race, region and severity. Hospital length of stay, operating room (OR)
time, costs and inpatient mortality were compared between the groups.
Results: A total of 624 matched pairs were identiﬁed for the ﬁnal analysis. Hospital
stay averaged 1.4 days longer in the DE patients (p<0.0001) compared to the Spi-
derFX Device patients. OR time was 38 minutes longer for DE patients (p¼0.02).
Total costs were higher but not statistically signiﬁcant for the DE group ($21,709 vs.
$19,948, p¼0.10). Room and board, pharmacy, laboratory and diagnostic costs were
all signiﬁcantly higher for DE than for the SpiderFX Device (p<0.05). The inpatient
mortality rate was higher in the DE group but not statistically signiﬁcant (1.8% vs.
0.80%, p¼0.13).
Conclusions: The use of the SpiderFX Device is strongly associated with shorter
hospital stays and shorter OR times. Cumulatively, these ﬁndings demonstrate
embolic protection devices such as the SpiderFX Device may signiﬁcantly reduce
consumption of hospital resources.
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Background: The purpose of this study was to identify the relationship between
below the knee (BTK) lesions and outcomes after endovascular treatment (EVT) of
chronic total occlusion (CTO) lesion in the superﬁcial femoral artery (SFA).
Methods: From June 2001 to November 20011, 209 atherosclerosis obliterans
patients underwent endovascular therapy for only SFA CTO lesions with self-
expanding stents. After the EVT, ﬁnal angiography was performed to evaluate the
blow the knee lesions and number of vessels (0 - 3) in BTK with CTO lesions were
counted. Within them, 120 limbs in 120 patients were performed 9 months follow up
angiography.
Results: In total, 31 patients (25.8%) were showed in-stent occlusion and 63 patients
(52.5%) were revealed in-stent restenosis including stent occlusion. The patients with
stent occlusion were more frequently observed BTK lesions at stent implantation
compared to the patients without stent occlusion (83.9% vs 58.4%; p¼0.02). Simi-
larly, the patients with in-stent restenosis were aloso more frequently observed BTK
lesions (76.2% vs 45.6%; p<0.001). The re-occlusion rate was signiﬁcantly higher in
the patients with 1 or 3 BTK lesions than patients without BTK CTO lesion. In
addition, the restenosis rate was also higher in the patients with 1 or 2 BTK CTO
lesions than patients without BTK lesions.
Conclusions: Re-occlusion and restenosis rate of the patients treated SFA CTO
lesions may be associated to the distal run-off vessel disease.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-533
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restenosis. Two years results from an Italian registry.
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Background: The patency rate of treated SFA has been improved through use of the
self-expanding nitinol stents. As the population with SFA stenting continues to
increase, occurrence of in-stent restenosis (ISR) has become a thoughtful problem.
The use of DEB has showed promising results in reducing restenosis recurrence in
coronary stents. Accordingly, the purpose of this prospective registry was to evaluate
the safety and efﬁcacy, at 2 years, of the use of drug-eluting balloons (DEB) for the
treatment of superﬁcial femoral artery (SFA) in-stent restenosis (ISR).
Methods: From December 2009 to December 2010, 39 consecutive patients under-
went PTA of SFA-ISR in our institution. All patients underwent conventional SFA
PTA and ﬁnal post-dilation with paclitaxel-eluting balloons (IN.PACT, Medtronic,
Minneapolis, Minnesota). Clinical follow-up and duplex ultrasonography scan were
performed at 30 days, and at 3, 6, 12, 18 and 24 months post-procedure. Repeat
angiography was performed when proximal ﬂow velocity ratio (PVR) was between
2.4 and 5.0 (intermediate restenosis) and when the patient had clinical symptoms or
> 5.0 (severe restenosis) regardless clinical symptoms and in case of stent occlusion.
Results: Technical and procedural success was achieved in every patient. No in-
hospital major adverse cardiac and cerebrovascular events occurred. At 2 years, 2
patient died (1 due to heart failure and 1 due to myocardial infarction). Primary
endpoint, primary patency rate at 24 months, was obtained in 70.3% (26 patients). The
presence of an occlusive restenosis at the time of treatment was not associated with an
increased restenosis rate, when compared with non-occlusive restenosis, at 2 years.
Conclusions: The data suggest that adjunctive use of DEB for the treatment of SFA-
ISR represents a potentially safe and effective therapeutic strategy. These data should
be considered hypothesis-generating to design a randomized trial.
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Background: We evaluated the clinical impact of different stenting strategies, to
cover or not to cover deep femoral arteries (DFA) in proximal superﬁcial femoral
artery (SFA) stenting, on the patency of SFA and to identify subgroups of patients for
whom these different stenting strategies have stronger association with better patency
for SFA bifurcation.
Methods: Between 2005 and 2012, 149 limbs stented at proximal SFA were retro-
spectively enrolled and classiﬁed into 2 groups according to stenting strategies; 85
limbs (57%) with coverage of DFA, group 1 and 64 limbs (43%) stented without
coverage of DFA, group 2. The fate of DFA and primary patency of SFA were
compared.
Results: Flow-limitation of DFA after stenting were observed in 14 limbs (9%) for
overall, 10 limbs (12%) in group 1 and 4 limbs (6%) in group 2 (p¼0.25). 85 limbs
had follow-up CT angiography within 2 yrs and no stenosis of DFA were observed in
both groups. Primary patency of SFA at 1 yr and 3 yr for overall limbs was 75% and
56%. Primary patency was not signiﬁcantly different between 2 groups (p¼0.22),
although there was a trend of higher patency in group 1 up to 2 yrs. In subgroup
analysis, there was a signiﬁcant interaction between stenting strategy and approach
method (p¼0.03). Group 1 had signiﬁcantly higher patency in subgroup of intra-
luminal approach (p¼0.01), whereas there were no difference in patency between 2
groups in subgroup of subintimal approach (p¼0.84).acts/POSTER/Endovascular Intervention B161
